| Name | Title | Contact Details |
|---|---|---|
Tony Meehan |
Chief Financial Officer | Profile |
Timothy Niedrist |
Associate Director of Financial Operations | Profile |
Ajit Roy |
Senior Director of Clinical R&D | Profile |
Helen Libman |
Senior Director, Analytical R&D | Profile |
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
AXM Pharma, Inc. is a global pharmaceutical company engaged in the production, marketing and distribution of pharmaceutical products in China. The Company produces, markets and distributes medicines in various dosages and forms in areas of medicinal
Degraft-Johnson & Associates is a Chadds Ford, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a platform of proprietary FASN inhibitors.
Our partner practices, including Barnet Dulaney Perkins Eye Center, Southwestern Eye Center, Retinal Consultants of Arizona, M&M Eye Institute, Abrams Eye Institute, Havasu Eye Center and Visage Aesthetics and Plastic Surgery have on average been in p...